Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia

Nature Immunology

Volumn 2, Issue 3, 2001, Pages 223-228

  Jain, Ashish ^a   Ma, Chi Adrian ^a   Liu, Shiyung ^b   Brown, Margaret ^b   Cohen, Jeffrey ^a   Strober, Warren ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHUK PROTEIN, HUMAN; CYTOKINE; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; PROTEIN SERINE THREONINE KINASE;

ADOLESCENT; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CHILD; ECTODERMAL DYSPLASIA; GENETIC LINKAGE; GENETICS; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGY; MALE; METABOLISM; MISSENSE MUTATION; PEDIGREE; T LYMPHOCYTE; X CHROMOSOME;

ADOLESCENT; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CHILD; CYTOKINES; ECTODERMAL DYSPLASIA; HUMANS; HYPERGAMMAGLOBULINEMIA; I-KAPPA B KINASE; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; LINKAGE (GENETICS); MALE; MUTATION, MISSENSE; NF-KAPPA B; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES; T-LYMPHOCYTES; X CHROMOSOME;

EID: 0035286726     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/85277     Document Type: Article

References (30)

1. Callard, R. E., Armitage, R. J., Fanslow, W. C. & Spriggs, M. K. CD-40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14, 559-564 (1993).
2. Notarangeto, L. D., Duse, M. & Ugazio, A. G. Immunodeficiency with hyper-IgM (HIM). Immunodef. Rev. 3, 101-121 (1992).
3. Kroczek, R. A. et al. Defective expression of CD40 ligand on T cells causes "X-linked immunodeficiency with hyper-IgM (HIGMI)". Immunol. Rev. 138, 39-59 (1994).
4. DiSanto, J. P., Bonnefoy, J. Y., Gauchat, J. F., Fischer, A. & de Saint Basile, G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361, 541-543 (1993).
5. Han, S. et al. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155, 556-567 (1995).
6. Xu, J. et al. Mice deficient for the CD40 ligand. Immunity 1, 423-431 (1994).
7. Renshaw, B. R. et al. Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. 180, 1889-1900 (1994).
8. Allen, R. C. et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259, 990-993 (1993).
9. Jain, A. et al. Defects of T-cell effector function and post-thymic maturation in X- linked hyper-IgM syndrome. J. Clin. Invest. 103, 1151-1158 (1999).
10. Monreal, A. W. et al. Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia. Nature Genet. 22, 366-369 (1999).
11. Kere, J. et al. X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nature Genet. 13, 409-416 (1996).
12. Jin, D. Y. & Jeang, K. T. Isolation of full-length cDNA and chromosomal localization of human NF-κB modulator NEMO to Xq28. J. Biomed. Sci. 6, 115-120 (1999).
13. Yamaoka, S. et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93, 1231-1240 (1998).
14. Israel, A. The IKK complex: an integrator of all signals that activate NF-κB? Trends Cell. Biol. 10, 129-133 (2000).
15. Ghosh, S., May, M. J. & Kopp, E. B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260 (1998).
16. Maniatis, T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 13, 505-510 (1999).
17. Smahi, A. et al. Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 405, 466-472 (2000).
18. Zonana, J. et al. A Novel X-Linked Disorder of Immune Deficiency and Hypohidrotic Ectodermal Dysplasia Is Allelic to Incontinentia Pigmenti and Due to Mutations in IKK-γ (NEMO). Am. J. Hum. Genet. 67 (2000).
19. Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 (2000).
20. Abbas, A. A., Licthman, A. H. & Prober, J. S. Cellular and Molecular Immunology. (Saunders, Philadelphia, 1998).
21. Klein, U., Rajewsky, K. & Kuppers, R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188, 1679-1689 (1998).
22. Grewal, I. S. & Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
23. Grammer, A. C. et al. TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J. Immunol. 161, 1183-1193 (1998).
24. Sutherland, C. L., Heath, A. W., Pelech, S. L., Young, P. R. & Gold, M. R. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157, 3381-3390 (1996).
25. Shu, U. et al. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25, 1125-1128 (1995).
26. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
27. Yan, M. et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290, 523-527 (2000).
28. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
29. Naito, A. et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4, 353-362 (1999).
30. Deng, L et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361 (2000).